ATTENTION: The software behind KU ScholarWorks is being upgraded to a new version. Starting July 15th, users will not be able to log in to the system, add items, nor make any changes until the new version is in place at the end of July. Searching for articles and opening files will continue to work while the system is being updated.
If you have any questions, please contact Marianne Reed at mreed@ku.edu .
DOX-Vit D, a Novel Doxorubicin Delivery Approach, Inhibits Human Osteosarcoma Cell Proliferation by Inducing Apoptosis While Inhibiting Akt and mTOR Signaling Pathways
dc.contributor.author | Maayah, Zaid H. | |
dc.contributor.author | Zhang, Ti | |
dc.contributor.author | Forrest, Marcus Laird | |
dc.contributor.author | Alrushaid, Samaa | |
dc.contributor.author | Doschak, Michael R. | |
dc.contributor.author | Davies, Neal M. | |
dc.contributor.author | El-Kadi, Ayman O. S. | |
dc.date.accessioned | 2020-12-02T15:55:08Z | |
dc.date.available | 2020-12-02T15:55:08Z | |
dc.date.issued | 2018-09-04 | |
dc.identifier.citation | Maayah, Z. H., Zhang, T., Forrest, M. L., Alrushaid, S., Doschak, M. R., Davies, N. M., & El-Kadi, A. (2018). DOX-Vit D, a Novel Doxorubicin Delivery Approach, Inhibits Human Osteosarcoma Cell Proliferation by Inducing Apoptosis While Inhibiting Akt and mTOR Signaling Pathways. Pharmaceutics, 10(3), 144. https://doi.org/10.3390/pharmaceutics10030144 | en_US |
dc.identifier.uri | http://hdl.handle.net/1808/30954 | |
dc.description | This work is licensed under a Creative Commons Attribution 4.0 International License. | en_US |
dc.description.abstract | Doxorubicin (DOX) is a very potent and effective anticancer agent. However, the effectiveness of DOX in osteosarcoma is usually limited by the acquired drug resistance. Recently, Vitamin D (Vit-D) was shown to suppress the growth of many human cancer cells. Taken together, we synthesized DOX-Vit D by conjugating Vit-D to DOX in order to increase the delivery of DOX into cancer cells and mitigate the chemoresistance associated with DOX. For this purpose, MG63 cells were treated with 10 µM DOX or DOX-Vit D for 24 h. Thereafter, MTT, real-time PCR and western blot analysis were used to determine cell proliferation, genes and proteins expression, respectively. Our results showed that DOX-Vit D, but not DOX, significantly elicited an apoptotic signal in MG63 cells as evidenced by induction of death receptor, Caspase-3 and BCLxs genes. Mechanistically, the DOX-Vit D-induced apoptogens were credited to the activation of p-JNK and p-p38 signaling pathway and the inhibition of proliferative proteins, p-Akt and p-mTOR. Our findings propose that DOX-Vit D suppressed the growth of MG63 cells by inducing apoptosis while inhibiting cell survival and proliferative signaling pathways. DOX-Vit D may serve as a novel drug delivery approach to potentiate the delivery of DOX into cancer cells. | en_US |
dc.description.sponsorship | Canadian Institutes of Health Research [Grant 106665] | en_US |
dc.description.sponsorship | U.S. National Cancer Institute [Grant R01CA173292] | en_US |
dc.publisher | MDPI | en_US |
dc.rights | © 2018 by the authors. Licensee MDPI, Basel, Switzerland. | en_US |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | en_US |
dc.subject | Doxorubicin | en_US |
dc.subject | MG63 | en_US |
dc.subject | Vitamin D | en_US |
dc.subject | DOX-Vit D | en_US |
dc.title | DOX-Vit D, a Novel Doxorubicin Delivery Approach, Inhibits Human Osteosarcoma Cell Proliferation by Inducing Apoptosis While Inhibiting Akt and mTOR Signaling Pathways | en_US |
dc.type | Article | en_US |
kusw.kuauthor | Zhang, Ti | |
kusw.kuauthor | Forrest, Marcus Laird | |
kusw.kudepartment | Pharmaceutical Chemistry | en_US |
dc.identifier.doi | 10.3390/pharmaceutics10030144 | en_US |
dc.identifier.orcid | https://orcid.org/0000-0001-7705-9025 | en_US |
dc.identifier.orcid | https://orcid.org/0000-0002-0293-6596 | en_US |
dc.identifier.orcid | https://orcid.org/0000-0002-7050-1471 | en_US |
kusw.oaversion | Scholarly/refereed, publisher version | en_US |
kusw.oapolicy | This item meets KU Open Access policy criteria. | en_US |
dc.identifier.pmid | PMC6161239 | en_US |
dc.rights.accessrights | openAccess | en_US |